Watson's income suffers despite revenue hike
This article was originally published in Scrip
Executive Summary
Watson Pharmaceuticals' net income slumped by 11% to $63 million in the third quarter after higher R&D and SG&A costs and income taxes more than offset a rise in the company's revenues.